Trodelvy: Cost, how it works, dosage, side effects, and more

Important note: This article is for educational purposes and is not medical advice. Trodelvy is a prescription cancer treatment given by IV infusion under oncology supervision. If you have urgent symptoms (fever, severe diarrhea, trouble breathing, swelling, fainting), contact your oncology team or emergency services right away.

What is Trodelvy?

Trodelvy (generic name: sacituzumab govitecan-hziy) is a targeted cancer medicine known as an antibody-drug conjugate (ADC). Think of an ADC like a “smart delivery truck”: it uses an antibody to find a target on cancer cells, then drops off a chemo-like payload where it’s needed most.

Trodelvy is FDA-approved for certain adults with unresectable locally advanced or metastatic breast cancer after prior treatments, including:

• Metastatic triple-negative breast cancer (mTNBC) after two or more prior systemic therapies (at least one in the metastatic setting).
• Hormone receptor (HR)-positive, HER2-negative metastatic breast cancer after endocrine-based therapy and at least two additional systemic therapies in the metastatic setting (HER2-negative includes IHC 0/1+ or IHC 2+/ISH–).

A quick “what it’s not” (because labels change)

Trodelvy previously had an accelerated-approval indication for locally advanced or metastatic urothelial cancer (bladder cancer). That indication was later removed from the U.S. labeling (the urothelial cancer accelerated-approval text was removed in late 2024). If you’re researching older articles, this is why you may see conflicting information. Always confirm the current indication with your oncology team.

How Trodelvy works (in plain English)

Trodelvy combines three key parts:

• An antibody that recognizes Trop-2, a protein often found at high levels on certain cancer cells.
• A “linker” that holds the medicine together until it reaches the right environment.
• SN-38, the active cancer-killing payload (a topoisomerase I inhibitor).

Here’s the general idea: Trodelvy binds to Trop-2–expressing cancer cells, is taken into the cell, and then releases SN-38. SN-38 interferes with how cancer cells repair DNA during replication, leading to DNA damage and cell death. Because Trodelvy can deliver SN-38 in a more targeted way than traditional chemotherapy, it aims to increase tumor impact while limiting (not eliminating) collateral damage to healthy tissue.

One important safety “don’t”

Trodelvy should not be substituted for, or used together with, other drugs that contain irinotecan or its active metabolite SN-38. In other words: no “double SN-38” experiments at home (or anywhere). Your oncology team will manage this, but it’s worth knowing why medication lists matter.

Dosage and how Trodelvy is given

Trodelvy is administered as an intravenous (IV) infusion in a clinic or infusion center. The standard schedule is:

• 10 mg/kg on Day 1 and Day 8 of a 21-day cycle.
• Treatment continues until disease progression or unacceptable toxicity.

How long does an infusion take?

• First infusion: typically over about 3 hours, with observation during and for at least 30 minutes after.
• Later infusions: may run over 1–2 hours if prior infusions were tolerated, with continued monitoring.

Premedication (aka “we’re not letting nausea win today”)

Before each dose, clinicians typically give medications to reduce the risk of:

• Infusion reactions (often using fever reducers and allergy-type medicines; steroids may be added if you’ve had a prior reaction).
• Chemotherapy-induced nausea and vomiting (CINV) (often a 2–3 drug regimen, such as dexamethasone plus a 5-HT3 blocker and/or an NK1 blocker).

Exact premeds vary by clinic protocol and your history.

Dose holds and dose reductions

Like many cancer therapies, Trodelvy dosing can be adjusted to keep treatment safer and more tolerable. If significant side effects occur, the team may:

• Hold a dose until recovery (for example, waiting for white blood cell counts to improve).
• Reduce the dose stepwise if severe side effects recur.

Typical dose reduction steps are:

• From 10 mg/kg (starting dose) → 7.5 mg/kg (first reduction)
• Then → 5 mg/kg (second reduction)
• If further reduction is needed, Trodelvy is often discontinued rather than reduced again.

What about kidney or liver problems?

Your team may take extra caution if you have liver disease, because SN-38 is processed through pathways affected by liver function. Mild renal impairment may not change dosing in many cases, but severe kidney or moderate/severe liver impairment can complicate decision-making. This is one reason oncologists are so obsessed with “just one more lab panel.”

Side effects: what’s common, what’s serious, and what to do

Trodelvy has a boxed warning (the FDA’s most prominent warning) for:

• Neutropenia (dangerously low neutrophils, a type of white blood cell)
• Diarrhea (which can become severe and lead to dehydration and other complications)

Boxed warning #1: Neutropenia (low white blood cells)

Neutropenia can happen earlysometimes in the first cycle. This matters because neutrophils help fight infection. Low counts can mean infections become more likely and more dangerous.

How your team manages it:

• Regular blood count monitoring
• Holding doses if counts are too low
• Using G-CSF (growth factor support) in people at higher risk of febrile neutropenia and as clinically indicated
• Rapid treatment if fever develops (because fever + neutropenia is an emergency in oncology)

Call your care team right away if you develop fever, chills, new cough, burning with urination, or feel suddenly “hit by a truck” without a good reason. Your team would rather hear from you early than meet you later in the emergency department.

Boxed warning #2: Diarrhea (don’t “tough it out”)

Diarrhea with Trodelvy can be severe. The clinical approach typically includes:

• Checking for infectious causes
• Starting loperamide promptly if infection is not suspected or ruled out
• Fluids and electrolytes as needed
• Holding Trodelvy and reducing the dose if diarrhea is severe or recurrent

Why this is a big deal: Severe diarrhea can lead to dehydration, electrolyte imbalances, and kidney strain. “It’s just diarrhea” is not the vibe we want hereespecially if you can’t keep fluids down, symptoms are worsening, or there’s blood.

Other common side effects

Many patients experience a mix of classic chemo-like side effects (because the payload is cytotoxic). Commonly reported issues include:

• Nausea and sometimes vomiting
• Fatigue (the “I could nap on a moving escalator” kind)
• Hair loss (alopecia)
• Low red blood cells (anemia)
• Decreased appetite
• Constipation (yes, diarrhea and constipation can both show uphuman bodies are chaotic)
• Abdominal discomfort

Serious but less common risks

Trodelvy can also cause serious reactions that require urgent evaluation, including:

• Hypersensitivity and infusion-related reactions (including rare severe allergic-type reactions)
• Severe nausea/vomiting not controlled with standard antiemetics
• Neutropenic colitis (inflammation/infection risk in the bowel when white blood cells are low)

Pregnancy, fertility, and breastfeeding

Because of how it works, Trodelvy can harm a developing fetus. Key points typically discussed in counseling include:

• Pregnancy testing before starting therapy for people who can become pregnant
• Using effective contraception during treatment and for a period after the last dose (often months)
• No breastfeeding during treatment and for a period after the final dose
• Possible fertility impacts (your oncologist may discuss fertility preservation options before treatment when relevant)

Genetics and drug interactions: the UGT1A1 connection

SN-38 (Trodelvy’s active payload) is processed in the body by an enzyme system involving UGT1A1. Some people have genetic variants (such as UGT1A1*28) associated with reduced enzyme activity, which can increase the risk of side effects like neutropenia and anemia. This doesn’t mean you can’t use Trodelvybut it does mean your team may monitor you extra closely.

Drug interactions: Some medications can inhibit or induce UGT1A1 and may affect SN-38 exposure. Your oncology pharmacist may advise avoiding certain interacting drugs when possible. The takeaway: bring a complete medication list, including supplements and herbal products. “It’s just a vitamin” has started many medical plot twists.

Trodelvy cost: what it can look like in the real world

Let’s be honest: the cost conversation is rarely fun, and cancer already took the fun budget.

Why Trodelvy can be expensive

Trodelvy is a specialty biologic therapy administered by infusion. Costs can include:

• The drug itself (priced per vial)
• Infusion center services (staffing, supplies, monitoring)
• Premedications and supportive meds (like anti-nausea drugs or growth factor)
• Lab tests and follow-up visits

A simple “vial math” example (to understand why bills get big fast)

Trodelvy dosing is weight-based. If someone weighs 70 kg, the Day 1 dose is 10 mg/kg = 700 mg, and the drug comes in 180 mg single-dose vials. That often means multiple vials per infusion. Then you do it again on Day 8. Even without quoting an exact price (which can vary by year, contracts, and site of care), you can see how the raw medication cost stacks quickly.

What insurance coverage often looks like

Because Trodelvy is given in a clinic, it’s frequently covered under the medical benefit (not the retail pharmacy benefit). Coverage details vary widely, but common scenarios include:

• Commercial insurance: Often requires prior authorization; patient cost may involve coinsurance until out-of-pocket maximums are met.
• Medicare: Infused drugs are often handled under Part B rules when administered in outpatient settings, and patients may face coinsurance unless they have supplemental coverage.
• Medicaid/VA/TRICARE: Coverage rules differ by program; copay card programs usually don’t apply to government insurance.

Financial assistance and support programs

Many patients don’t pay “sticker price.” Support may include:

• Manufacturer support services that help verify coverage and navigate prior authorizations.
• Copay support for eligible commercially insured patients (program limits and eligibility rules apply).
• Patient assistance programs for eligible uninsured or underinsured patients.
• Independent foundations that sometimes help with copays for qualifying diagnoses (availability varies).

Practical tip: Ask the infusion center’s financial counselor for a benefits investigation and an out-of-pocket estimate before the first infusion. It won’t be perfect, but it’s far better than being surprised by a bill that arrives like it owns the place.

Questions to ask your oncology team

• Is Trodelvy being recommended because of my cancer subtype, prior treatments, or both?
• What labs will you monitor, and how often?
• What’s your plan for preventing or treating neutropenia (including G-CSF)?
• What should I do at the first sign of diarrhea, and when do I call the clinic?
• What side effects should trigger an urgent call (fever, dehydration, breathing symptoms, rash, etc.)?
• How will billing work at this infusion center (medical benefit vs pharmacy benefit)?
• Who can help me apply for financial assistance if needed?

Real-world experiences (about ): what treatment weeks can feel like

Clinical trial tables and FDA labels are essentialbut they don’t capture what it’s like to live on a “Day 1 / Day 8 / repeat” calendar. In real life, many people describe Trodelvy treatment as a rhythm you learn over time: infusion days, a few days of recovery, then a “good stretch,” then back again.

Infusion day logistics are often the first surprise. People talk about packing like they’re going to an airport with fewer snacks and more paperwork: a phone charger, something warm (infusion rooms are basically professional-grade air conditioning), and a plan for boredom. The first infusion can take longer, and the post-infusion observation can make the day feel like an all-day eventeven when the actual “medicine time” is only a few hours.

Nausea and appetite changes can be a moving target. Some patients say premedications make a huge difference; others need their anti-nausea plan adjusted after the first cycle or two. A common theme is that “safe foods” become a strategy: simple meals, bland staples, small portions, and staying hydrated in whatever form is tolerable (ice chips, flavored electrolyte drinks, soup). The goal isn’t culinary excellenceit’s keeping the body fueled enough to recover.

Fatigue is frequently described as unpredictable. People often report learning to budget energy like money: spend it on what matters, and stop apologizing for needing rest. Some plan important tasks on their better days and keep the day after infusion intentionally light. A surprisingly helpful mindset is treating recovery as part of treatment, not a personal failure to “push through.”

Diarrhea anxiety is real, especially because it’s specifically called out as a serious risk. Many patients say they feel more confident once they have a clear clinic-approved plan: what to take, how much, when to call, and what symptoms mean “don’t wait.” Having supplies ready at home can reduce stress (your care team can advise what’s appropriate). The big emotional shift tends to be moving from embarrassment to practicalitybecause dehydration doesn’t care if anyone feels awkward.

Blood counts and infection precautions can affect day-to-day life. Some people describe becoming more aware of “small” symptomslike chills, sore throat, or feverbecause they know low neutrophils can change the stakes. Many also mention that growth factor support (when prescribed) can help maintain the treatment schedule, though it adds another layer of side effects and planning.

Cost and insurance navigation is often its own side quest. Patients commonly rely on social workers, financial counselors, and manufacturer support programs to decode benefits, prior authorizations, and copays. The experience is frequently described as frustratingbut also manageable with the right help. If there’s one consistent piece of advice patients share, it’s this: don’t do the financial paperwork alone if you don’t have to. Ask for support early.

Finally, many people describe the emotional experience as a mix of hope and realism: hoping for meaningful disease control, while staying grounded about side effects and uncertainty. In that sense, Trodelvy isn’t just a medicationit’s a routine, a set of coping skills, and a team effort that includes clinicians, caregivers, and the patient learning what their body needs week by week.

Conclusion

Trodelvy is an antibody-drug conjugate used for certain pretreated metastatic breast cancers, delivering the SN-38 payload to Trop-2–expressing cancer cells. It’s given by IV infusion on Days 1 and 8 of a 21-day cycle, with careful monitoring for its most important risks: neutropenia and diarrhea. While the cost can be high, insurance coverage plus financial support programs may reduce out-of-pocket burden. If Trodelvy is part of your treatment plan, the best outcomes usually come from proactive side-effect management, clear communication with your oncology team, and getting financial navigation help early.